Business
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Abstract data demonstrate encouraging antitumor activity in first-line GEA Full ESMO presentation available September 16 at 8:30 am CEST, 2:30 am ET
About this update from Zymeworks Inc.
[{"type":"text","content":"\n\nAbstract data demonstrate encouraging antitumor activity in first-line GEA\n\n\nFull ESMO presentation available September 16 at 8:30 am CEST, 2:30 am ET\n\n\nConference call and webcast with principal investigator, Dr. Geoffrey Ku, on September 16 at 7:30 am ET\n\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nZymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody, in first-line HER2-expressing GEA. An updated and expanded data set will be presented at the ESMO Annual Congress taking place virtually on September 16-21, 2021.\n\nAbstract highlights from March 18, 2021 data cut:\n\n\nThirty patients had been treated with zanidatamab in combination with standard of care chemotherapy (either mFOLFOX6, CAPOX, or FP), and 14 patients remained on treatment.\n\n\nThe confirmed objective response rate was 68.2% and the disease control rate was 90.9% in 22 HER2-positive response-evaluable patients.\n\n\nTreatment related adverse events were generally consistent with previous reports of zanidatamab and/or the chemotherapy regimens, with the majority reported as Grade 1 or 2 in severity.\n\n\n“The initial data from the abstract highlight an encouraging objective response rate for zanidatamab combined with standard of care chemotherapy in patients with metastatic HER2-positive GEA,” said Neil Josephson, M.D., Zymeworks’ Interim Chief Medical Officer. “We’re looking forward to presenting at the Congress the full updated data, which further support zanidatamab’s potential as the new foundational HER2-targeted therapy.”\n\nESMO Presentation\nThe abstract is available on the ESMO conference website. The presentation will be available on Thursday, September 16 at 8:30 am CEST, 2:30 am ET, to conference registrants on the ESMO conference website as well as to the general public on the Zymeworks website at https://ir.zymeworks.com/events-and-presentations.\n\nTitle: Phase (Ph) 2 Study of Zanidatamab + Chemotherapy (chemo) in First Line (1L) HER2-expressing Gastroesophageal Adenocarcinoma (GEA)\nLead Author: Geoffrey Ku, M.D., Memorial Sloan Kettering Cancer Center, New York, NY, US\nAbstract: 3678\nE-poster: 1380P\n\nConference Call and Webcast\nThe c...